AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
Read how SAGA Diagnostics’ AACR 2026 Pathlight data could reshape ctDNA monitoring in metastatic breast and ovarian cancer.
What Accent Therapeutics’ AACR 2026 ATX-295 update reveals about the next wave of precision oncology targets
Accent Therapeutics is expanding the ATX-295 story in solid tumors. Read what the new AACR 2026 data could change and what risks remain.